Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: A randomized first human dose trial in healthy subjects

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 7, 2011, Pages 1368-1374

  Moss J ^a   Rosholm, A ^a   Lauren A ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

GlycoPEGylated rFVIIa; Half life; Hemophilia; Inhibitor; Long acting; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 7A; MACROGOL; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG HALF LIFE; DRUG SAFETY; HEMOPHILIA; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOEMBOLISM;

ANTIBODIES, NEUTRALIZING; CHEMOPREVENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR VIIA; HALF-LIFE; HEMOPHILIA A; HUMANS; MALE; PROTHROMBIN TIME; RECOMBINANT PROTEINS;

EID: 79959828057     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04344.x     Document Type: Article

References (22)

1. Santagostino E, Morfini M, Auerswald GK, Benson GM, Salek SZ, Lambert T, Salaj P, Jimenez-Yuste V, Ljung RC. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia 2009; 15: 983-9.
2. Berntorp E, Shapiro A, Astermark J, Blanchette VS, Collins PW, Di Michele D, Escuriola C, Hay CR, Hoots WK, Leissinger CA, Negrier C, Oldenburg J, Peerlinck K, Reding MT, Hart C. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006; 12 (Suppl. 6): 1-7.
3. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost 2003; 29: 69-76.
4. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7: 517-22.
5. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-7.
6. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
7. Klarmann D, Martinez Saguer I, Funk MB, Knoefler R, von Hentig N, Heller C, Kreuz W. Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 2008; 14: 44-9.
8. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
9. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, Di Michele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
10. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898-902.
11. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, Serban MA. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
12. Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 2007; 13: 527-32.
13. Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005; 16: 259-66.
14. Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2008; 65: 3-11.
15. Keating GM, Curran MP. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2003; 63: 701-30.
16. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
17. Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007; 35: 9-16.
18. Stennicke HR, Ostergaard H, Bayer RJ, Kalo MS, Kinealy K, Holm PK, Sørensen BB, Zopf D, Bjørn SE. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives. Thromb Haemost 2008; 100: 920-8.
19. Ghosh S, Sen P, Pendurthi UR, Rao LV. Activity and regulation of glycoPEGylated factor VIIa analogs. J Thromb Haemost 2008; 6: 1525-33.
20. Sorensen BB, Kjalke M, Zopf D, Bjorn SE, Stennicke HR. Platelet-dependent activity of GlycoPEGylated rFVIIa. Blood 2007; 110: 923A-4A.
21. Scharling B, Nielsen GG, Klitgaard T, Skovsted TA, Moss J, Segel S, Larsen LF. Comparison of coagulant activity of factor VII and activated factor VII activity assays when used for determination of recombinant activated factor VII levels in plasma. Blood Coagul Fibrinolysis 2007; 18: 677-84.
22. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009; 108: 1433-46.